OBGYN.net Broadcasting presents Part VII of a series on Weight Loss Surgery. This series is unique in that we follow the patient from pre-op to one year post-op.
<a href="http://av.obgyn.net/ramgen/roberta/partVII/part7.rm">Click here to experience the presentation </a></A>
OBGYN.net Broadcasting presents Part VII of a series on Weight Loss Surgery. This series is unique in that we follow the patient from pre-op to one year post-op. Funding for this project was made possible by InnerDyne®, Inc., BioEnterics, Corp., and Richard Wolf. The patient is Roberta Speyer, President and Publisher of OBGYN.net. In Part VII, Marshall Smith, MD, MediSpecialty.com Publisher, and Roberta talked about her weight loss. This interview is 4 months post-op.
At this time, three years post-op, Roberta is satisfied with the outcome of her surgery and hopes you have found her story helpful in your search for answers. Please direct any questions about LAP BAND surgery to your personal physician, or email the product makers directly at: http://www.inamed.com/contact/bio_patient.cgi. Due to time restraints Roberta Speyer and the OBGYN.net team cannot respond to personal emails. See Professor Rudolf Weiner's website about Weight Loss Surgery to see if this option is right for you. Visit www.profweiner.com.
click on the play button above to start the video
You will need RealPlayer to download the streaming video of this presentation. If you need a FREE copy of RealPlayer you can download it here.
Text version of this presentation
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More